Skip to main content
Log in

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin analogs: A Case Series

  • Published:
Lung Aims and scope Submit manuscript

Abstract

Objectives

DIPNECH is a rare pre-neoplastic condition that often presents with a variety of non-specific pulmonary symptoms and sometimes seen in conjunction with pulmonary carcinoid tumors. There are very limited data on use of somatostatin analogs in patients with DIPNECH. We review the long-term outcomes of somatostatin analog therapy with regard to symptom control in patients with DIPNECH.

Materials/Methods

Retrospective study out of our extensive registry of over 2000 neuroendocrine tumors identifies 184 pulmonary neuroendocrine tumors. Out of this, there were five histopathologically confirmed cases of DIPNECH. Appropriate institutional review board permission was taken for this analysis.

Results

All 5 patients were females, with a mean age at diagnosis was 65.5 years. Follow-up period includes 1–5 years. Cough was the presenting complaint in all five patients described as mostly dry, except for one patient who had productive early morning cough. Other symptoms seen in one of our patients included wheezing, flushing, and fluctuating blood pressure. No one reported weight loss, hemoptysis, and shortness of breath. One of our patients had a benign thyroid nodule and two patients had previous history of breast cancer. All five of our patients were histopathologically diagnosed by lung biopsy. 4 out of 5 patients were started on a somatostatin analog. All four patients reported drastic improvement in cough. One patient reported mild abdominal discomfort and diarrhea as side effects but remained on treatment.

Conclusions

From our single institution review of neuroendocrine pulmonary tumor cases, we found only five cases of DIPNECH, which reaffirms rare nature of the pathology. It primarily affects females over 60 years with dry cough as the most common presenting symptom. Most of our patients responded to treatment with a somatostatin analog and had significant improvement in their presenting symptoms. Somatostatin analogs were well tolerated resulting in significant resolution of presenting symptoms in most of our patients. Further research is needed; however, a trial of somatostatin analogs should be considered in the treatment of patients with DIPNECH with responders being treated long term.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Felton WL, Liebow AA, Lindskog GE (1953) Peripheral and multiple bronchial adenomas. Cancer 6:555–566

    Article  PubMed  Google Scholar 

  2. Aguayo SM, Miller YE, Waldron JA Jr et al (1992) Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med 327:1285–1288

    Article  CAS  PubMed  Google Scholar 

  3. Davies SJ, Gosney JR, Hansell DM et al (2007) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 62:249–252

    Article  Google Scholar 

  4. Aubry MC, Thomas CF Jr, Jett JR, Swensen SJ, Myers JL (2007) Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. Chest 131:1635–1643

    Article  PubMed  Google Scholar 

  5. Beasley MB, Brambilla E, Travis WD (2005) The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 40:90–97

    Article  PubMed  Google Scholar 

  6. Gorshtein A, Gross DJ, Barak D, Strenov Y, Refaeli Y, Shimon I, Grozinsky-Glasberg S (2012) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entity. Cancer 118(3):612–619

    Article  PubMed  Google Scholar 

  7. Kerr KM (2001) Pulmonary preinvasive neoplasia. J Clin Pathol 54:257–271

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Lee JS, Brown KK, Cool C, Lynch DA (2002) Diffuse pulmonary neuroendocrine cell hyperplasia: radiologic and clinical features. J Comput Assist Tomogr 26:180–184

    Article  PubMed  Google Scholar 

  9. Ge Y, Eltorky MA, Ernst RD, Castro CY (2007) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Ann Diagn Pathol 11:122–126

    Article  PubMed  Google Scholar 

  10. Adrienne A, Nassar MD et al (2011) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. A systematic overview. Am J Respir Crit Care Med 184(1):8–16. doi:10.1164/rccm.201010-1685PP

    Article  Google Scholar 

  11. Zhou H, Ge Y, Janssen B et al (2014) Double lung transplantation for diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. J Bronchol Interv Pulmonol 21(4):342–345

    Article  Google Scholar 

  12. Jones MH, Wales D et al (2013) Diffuse idiopathic pulmonary endocrine cell hyperplasia (DIPNECH) requiring bilateral sequential lung transplant. Eur Respir J 42(Suppl 57):P2179

    Google Scholar 

  13. Anthony L, Freda PU (2009) From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 25:2989–2999

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Susini C, Buscail L (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17:1733–1742

    Article  CAS  PubMed  Google Scholar 

  15. Bousquet C et al (2012) Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab 97:727–737

    Article  CAS  PubMed  Google Scholar 

  16. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D (2007) Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92(5):1592–1599

    Article  CAS  PubMed  Google Scholar 

  17. Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-Guibert J, Pyronnet S, Bousquet C (2014) Somatostatin analogs:does pharmacology impact antitumor efficacy? Trends Endocrinol Metab 25(3):115–127

    Article  CAS  PubMed  Google Scholar 

  18. Pyronnet S et al (2008) Antitumor effects of somatostatin. Mol Cell Endocrinol 286:230–237

    Article  CAS  PubMed  Google Scholar 

  19. Laklai H et al (2009) Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc Natl Acad Sci USA 106:17769–17774

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. PROMID Study Group, Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. Clin Oncol 27(28):4656–4663. doi:10.1200/JCO.2009.22.8510

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert A. Ramirez DO, FACP.

Ethics declarations

Conflict of interest

Robert A. Ramirez is a consultant for bioTheranostics Inc. No financial support was obtained for our study. The authors had full control of the design of the study, methods used, outcome parameters and results, analysis of data, and production of the written report. Aman Chauhan has no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chauhan, A., Ramirez, R.A. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin analogs: A Case Series. Lung 193, 653–657 (2015). https://doi.org/10.1007/s00408-015-9754-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-015-9754-2

Keywords

Navigation